Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veverimer in Adults With Osteopenia
NCT07473713Phase 1Recruiting
- Sponsor
- Tufts Medical Center
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of veverimer in osteopenia (3 arms), sponsored by Tufts Medical Center. Primary endpoint: 24-hour Urinary Net Acid Excretion at 8 weeks. Started Apr 2026; status: recruiting.
02
Drugs
veverimer
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT07473713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473713.